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Identification of Glycan Structure Alterations on
Cell Membrane Proteins in Desoxyepothilone B
Resistant Leukemia Cells*□S
Miyako Nakano‡, Rohit Saldanha§, Anja Go¨bel§, Maria Kavallaris§¶‡‡,
and Nicolle H. Packer‡**‡‡
Resistance to tubulin-binding agents used in cancer is
often multifactorial and can include changes in drug ac-
cumulation and modified expression of tubulin isotypes.
Glycans on cell membrane proteins play important roles in
many cellular processes such as recognition and apopto-
sis, and this study investigated whether changes to the
glycan structures on cell membrane proteins occur when
cells become resistant to drugs. Specifically, we investi-
gated the alteration of glycan structures on the cell mem-
brane proteins of human T-cell acute lymphoblastic leu-
kemia (CEM) cells that were selected for resistance to
desoxyepothilone B (CEM/dEpoB). The glycan profile of
the cell membrane glycoproteins was obtained by se-
quential release of N- and O-glycans from cell membrane
fraction dotted onto polyvinylidene difluoride membrane
with PNGase F and -elimination respectively. The re-
leased glycan alditols were analyzed by liquid chromatog-
raphy (graphitized carbon)-electrospray ionization tan-
dem MS. The major N-glycan on CEM cell was the core
fucosylated 2–6 monosialo-biantennary structure. Re-
sistant CEM/dEpoB cells had a significant decrease of
2–6 linked sialic acid on N-glycans. The lower 2–6
sialylation was caused by a decrease in activity of -gal-
actoside 2–6 sialyltransferase (ST6Gal), and decreased
expression of the mRNA. It is clear that the membrane
glycosylation of leukemia cells changes during acquired
resistance to dEpoB drugs and that this change occurs
globally on all cell membrane glycoproteins. This is the
first identification of a specific glycan modification on the
surface of drug resistant cells and the mechanism of this
downstream effect on microtubule targeting drugs may
offer a route to new interventions to overcome drug
resistance. Molecular & Cellular Proteomics 10:
10.1074/mcp.M111.009001, 1–12, 2011.
Epothilones are a promising class of tubulin-binding agent
that stabilize microtubules against depolymerization and that
have shown promising preclinical and clinical activity. An
analog of epothilone B (Ixabepilone, BMS-247550, aza-EpoB)
has been approved for the treatment of drug refractory met-
astatic breast cancer (1). Epothilones target -tubulin on the
/-tubulin heterodimer, inducing potent mitotic arrest and
cell death (2, 3). Resistance to tubulin-binding agents such as
the vinca alkaloids, taxanes, and epothilones has primarily
been associated with the cellular target of the drug, tubulin
mutations and altered expression of specific tubulin isotypes
(4). We have previously described the selection and charac-
terization of T-cell acute lyphoblastic leukemia cells selected
for resistance to an epothilone B analog, Z12, 13-desoxye-
pothilone B (dEpoB)1 (5, 6). These dEpoB resistant cells ac-
quired multiple alterations associated with microtubules, in-
cluding increased expression of III-tubulin, increased
expression of MAP4, and mutations in I-tubulin (6).
It is well known that apoptosis plays a role in preventing
cancer. If a cell is unable to undergo apoptosis because of a
mutation or biochemical inhibition, it can continue to divide
and develop into a tumor. It is also known that protein glyco-
sylation changes with apoptosis in different biological sys-
tems. Recently, Malagolini et al. reported that expression of
2–6 sialylated lactosamine chains resulted in apoptotic and
necrotic death of cell lines from different histological origin,
(colon, breast, pancreas, and bladder cancer) (7). Honma et al.
reported a relationship between apoptosis and alteration of
the glycosylation pathway in a human breast cancer cell line
resistant to docetaxel, an agent that, like epothilone, stabilizes
microtubules against depolymerization. In this study, regula-
tion of the gene encoding ribophorin II (RPN2), which is part of
the N-oligosaccharyl transferase complex, efficiently induced
apoptosis of docetaxel-resistant human breast cancer cells
(MCF7-ADR cells) in the presence of docetaxel. RPN2 silenc-
ing induced reduced glycosylation of the P-glycoprotein, as
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well as decreased membrane localization, thereby sensitizing
MCF7-ADR cells to docetaxel (8). These two reports focused
on the relative alteration of glycan structures using lectin
staining or gel migration changes on SDS-PAGE, but did not
identify the actual glycan structures associated with these
drug resistance mechanisms.
Glycans on glycoproteins are classified into two types;
N-glycan (attached to the Asn residue in the Asn-X-Ser/Thr
sequon) and O-glycan (attached to Ser/Thr residues). All N-
glycans have a common core structure, Man1–6(Man1–
3)Man1–4GlcNAc1–4GlcNAc1-, and are classified into
three types: (1) high-mannose type, in which only Man resi-
dues are attached to both of the Man1–6 and Man1–3 arms
of the core structure; (2) hybrid type, in which Man residues
are attached to only the Man1–6 arm, an “antennae” struc-
ture produced through the action of N-acetylglucosaminyl-
transferases being attached to the Man1–3 arm; and (3)
complex type, in which the “antennae” structure is attached
to both the Man1–6 and Man1–3 arms.
Detailed analysis of changes in glycan structures can be
used to identify the specific enzyme(s) or gene(s) involved in
glycosylation-related pathways involved in drug resistance
mechanisms. This paper describes the alterations to glycan
structures on cell membrane proteins of CEM cells with ac-
quired resistance to dEpoB that were not present in the pa-
rental drug sensitive CEM cells. Thus, alterations to the gly-
cans attached to cell membrane proteins may contribute to
the phenotype associated with dEpoB resistance.
EXPERIMENTAL PROCEDURES
Materials—N-Glycosidase F (PNGase F, EC 3.5.1.52, recombinant
cloned from Flavobacterium meningosepticum and expressed in
E. coli) was purchased from Roche Diagnostics (Mannheim, Ger-
many). Alpha2–3 sialidase was from Takara Bio (Shiga, Japan).
Alpha2–3,6 sialidase, 2–3,6,8,9 sialidase and 1–3/4 fucosidase
were from Northstar bioproducts (East Falmouth, MA). Beta1–4 ga-
lactosidase was from ProGlycAn (Wien, Austria). Polyvinylidene diflu-
oride (PVDF) (0.2 m, for sequencing, 7  8.4 cm) was purchased
from Bio-Rad (Hercules, CA). Cation-exchange columns were made
of (30 mg) Dowex 50W-X8 resin (Supelco, Bellefonte, PA) packed on
top of a 10 l ZipTip of reversed phase C8 (Millipore, Billerica, MA).
The resins were protonated with 1 M HCl (50 l, 3 times), were washed
with methanol (50 l, 3 times), and then equilibrated with water (50 l,
3 times) before use. Microtiter plates (96-well flat bottom) were pur-
chased from Costar. Premade SDS-PAGE gels (4–12% (w/v), Tris-
Glycine, 12-well), LDS buffer (40% (v/v) glycerol, 4% (w/v) lithium
dodecyl sulfate, 0.8 M triethanolamine-Cl (pH 7.6), 4% (w/v) Ficoll 400,
0.025% (w/v) Phenol Red, 0.025% (w/v) Brilliant blue G250 and 2 mM
EDTA) and running buffer (SDS Run Buffer x20) were purchased from
PAGEgel INC (San Diego, CA). All other chemicals were purchased
from Sigma-Aldrich. Other reagents and solvents were of HPLC or
LC/MS grade.
Cell Culture and Preparation of Resistant Cells—A human T-cell
acute lymphoblastic leukemia cell line, CCRF-CEM (CEM), was
maintained in RPMI 1640 containing 10% (w/v) fetal calf serum as
suspension cultures. CEM cells were previously selected by multi-
ple stepwise treatments with increasing concentrations of dEpoB
(6). The resulting cell lines have since been maintained in drug-free
media and are routinely screened and free of mycoplasma. Cells
were grown to mid-log phase, collected by centrifugation at 1000
rpm and washed with phosphate-buffered saline (PBS) three times,
and cell pellets were stored at 80 °C before glycan analysis.
Cell Membrane Preparation—Cell pellets (1  107 cells) were ho-
mogenized in 2 ml of lysis buffer containing 50 mM Tris-HCl (pH 7.4),
0.1 M NaCl, 1 mM EDTA, and protease inhibitor mixture (Roche Diag-
nostics, Mannheim, Germany) using a polytron homogenizer (Omni
TH homogenizer, Omni International, Inc., VA; 15 s, 7 times on ice
bath). We performed the following preparation according to the pro-
cedure reported by Lee et al. (9) with some modifications. The ho-
mogenized cells were centrifuged at 2000  g for 20 min at 4 °C to
precipitate nuclei and unlyse cells. The supernatant was diluted with
2 ml of Tris-buffer (20 mM Tris-HCl (pH 7.4), 0.1 M NaCl) and then were
sedimented by ultracentrifugation at 120000  g for 80 min at 4 °C.
The supernatant was discarded, and the membrane pellet was sus-
pended in 100 l Tris-buffer. After adding 400 l Tris-buffer contain-
ing 1% (v/v) Triton X-114, the suspended mixture was homogenized
by pipeting strongly (9–11). The homogenate was chilled on ice for 10
min and incubated at 37 °C for 20 min and then phase partitioned by
centrifugation at 1000  g for 3 min. The upper aqueous phase was
removed. The lower detergent phase was further mixed with 1 ml of
ice-cold acetone and kept at 25 °C overnight to precipitate proteins
and remove any detergent. After centrifugation at 1000  g for 3 min,
the precipitated cell membrane proteins were stored at 25 °C if not
used immediately.
Enzymatic Release and Purification of N-glycans from Cell Mem-
brane Proteins—The precipitated membrane proteins were dissolved
with 10 l 8 M Urea. The solubilized proteins were dotted (2.5 l  4
times) onto polyvinylidene difluoride (PVDF) membrane prewetted
with ethanol. After drying the PVDF membrane at room temperature
overnight, the PVDF membrane was washed with ethanol for 1 min
and then washed three times for 1 min with water. The protein on the
membrane was stained for 5 min with Direct Blue 71 (800 l solution
A: 0.1% (w/v) Direct Blue 71(Sigma-Aldrich) in 10 ml solution B: acetic
acid : ethanol : water  1:4:5). After destaining with solution B for 1
min, the PVDF membrane was dried at room temperature for 4 h. N-
and O- glycans were released from the dotblotted proteins essentially
by the method of Wilson et al. (12) with some modifications. Protein
stained blue were cut from the PVDF membrane and placed in sep-
arate wells of a 96-well microtiter plate. The spots were then covered
with 100 l of 1% (w/v) poly(vinylpyrrolidone) 40000 in 50% (v/v)
methanol, agitated for 20 min, and washed with water (100 l  5
times). PNGase F (3U in 10 l of 30 mM phosphate buffer (pH 7.3))
was added to each well and incubated at 37 °C for 15 min. An
additional 10 l of water was added to each well and incubated at
37 °C overnight to release N-glycans. During the incubation, the
sample wells were sealed with amplification tape to prevent evapo-
ration. To collect the released N-glycans, the samples were sonicated
(in the 96-well plate) for 10 min, and the released N-glycans (20 l) were
transferred to 1.5-ml polypropylene tubes. The sample well was washed
with water (50 l twice), and the washings combined. To completely
generate the reducing terminus, ammonium acetate buffer (100 mM, pH
5.0, 20 l) was added to the released N-glycans for 1 h at room
temperature. After evaporating to dryness, the glycans were reduced
with 20 l of 1 M NaBH4 in 50 mM KOH at 50 °C for 3 h. One microliter
of acetic acid was added to stop the reaction, and the N-glycan alditols
were desalted using a cation-exchange column. The glycan alditols
were eluted with water (50 l twice), dried, and the remaining borate
was removed by the addition of (100 l 3) methanol and drying under
vacuum. The glycan alditols were resuspended in 10 mM NH4HCO3 (20
l) immediately before glycan analysis by liquid chromatography-elec-
trospray ionization mass spectrometry (LC-ESI MS).
Chemical Release and Purification of O-glycans from Cell Mem-
brane Proteins—After the removal of the N-glycans, each protein spot
Alterations of Glycans in Drug Resistance
10.1074/mcp.M111.009001–2 Molecular & Cellular Proteomics 10.11
 by guest on January 30, 2020
https://w
w
w
.m
cponline.org
D
ow
nloaded from
 
remaining on the membrane was rewet with 2.5 l of methanol. A
solution of 0.5 M NaBH4 in 50 mM KOH (20 l) was applied, and the
spots were incubated for 16 h at 50 °C in order to release O-glycan
alditols. After adding 2 l of acetic acid to stop the reaction, the same
procedures as for the clean up of N-glycan alditols was used.
LC-ESI MS for Analysis of Glycan Alditols—Both N- and O-glycan
alditols were separated using a HyperCarb porous graphitized carbon
column (5 m HyperCarb, 300 m I.D.  100 mm, Thermo Hypersil,
Runcorn, UK) under the following gradient conditions. The separation
of N-glycans was performed using a sequence of isocratic and two
segmented linear gradients: 0–8 min, 10 mM NH4HCO3; 8–53 min,
6.75–15.75% (v/v) CH3CN in 10 mM NH4HCO3; 53–73 min, 15.75–
40.5% (v/v) CH3CN in 10 mM NH4HCO3; and increasing to 81% (v/v)
CH3CN in 10 mM NH4HCO3 for 6 min and re-equilibrated with 10 mM
NH4HCO3 for 4 min. The separation of O-glycans was performed with
an isocratic and two segmented linear gradients: 0–8min, 10 mM
NH4HCO3; 8–33 min, 0–22.5% (v/v) CH3CN in 10 mM NH4HCO3;
33–37 min, 22.5–40.5% (v/v) CH3CN in 10 mM NH4HCO3; and in-
creasing to 81% (v/v) CH3CN in 10 mM NH4HCO3 for 6 min and
re-equilibrated with 10 mM NH4HCO3 for 4 min. The HPLC flow rate
was 500 l/min with a split ratio of 1/100 to give a final flow rate of 5
l/min through the column (UltiMate 3000, Dionex, USA). The injec-
tion volume of samples was 5 l. In the MS (Esquire HCT, Bruker
Daltonics GmbsH, Bremen,Germany), the voltage of the capillary
outlet was set at 3 kV, and the temperature of the transfer capillary
was maintained at 300 °C. The flow rate of nitrogen gas for drying was
6 L/min. The MS spectra were obtained in the negative ion mode over
the mass rangem/z 100 tom/z 2500. The scan rates were 8100 amu/s
for the MS mode and the MS/MS mode. Monoisotopic masses were
assigned with possible monosaccharide compositions using the Gly-
coMod tool available on the ExPASy server (http://au.expasy.org/
tools/glycomod; mass tolerance for precursor ions is  0.1 Da) and
the proposed oligosaccharide structures were further verified through
annotation using a fragmentation mass matching approach based on
the MS/MS data. Validation of the technical reproducibility of the
analytical conditions such as retention time and mass number was
carried out using known glycans derived from fetuin (supple-
mental Fig. S1), before analyzing any experimental samples.
The Relative Abundance of N-glycan and O-glycan Structures on
Cell Membrane Glycoprotein of CEM and CEM/dEpoB Cells—The
relative abundance of each glycan structure on the cell membrane
glycoproteins of CEM and drug-resistant cells was calculated based
on the peak area of the extracted ion chromatogram (EIC) of the
corresponding glycan structure, after processing of the peaks
(smoothing algorithm; Gauss, smoothing widths; 3 pnts (for N-glycan)
or 1 pnts (for O-glycan) using Bruker Daltonics DataAnalysis software
version 3.4. The peak areas of all the glycan structures released from
each sample was summed and set to 100%, and the relative abun-
dance (%) was calculated for each glycan structure.
Specific Sialidase Digestions of Glycan Samples—N- and O-glycan
samples were digested with three different sialidases to determine the
specific linkage of sialic acid. Three portions (1 l, 0.5 l, and 0.5 l)
of the N-glycan alditols were mixed with 250 mM ammonium acetate
(pH 6.0, 2 l), and made up to 9 l with water respectively. Alpha2–3
sialidase (50 mU, 1 l), 2–3,6 sialidase (15 mU, 1 l), and 2–3,6,8,9
sialidase (5 mU, 1 l) were added to the mixtures respectively and
incubated at 37 °C overnight. After heating at 99 °C for 2 min to stop
the reaction, each digest was analyzed by LC-EIS MS.
Specific Fucosidase and Galactosidase Digestions of Glycan Sam-
ples—Desialylated N-glycan samples were digested with 1–3,4 fu-
cosidase and 1–4 galactosidase for further structural information.
N-glycan alditols (1 l) were desialylated by incubating with 100 l of
2 M acetic acid at 80 °C for 2 h and were evaporated to dryness. The
residue was dissolved in 50 mM ammonium acetate (pH 6.0, 30 l)
and was equally divided into three equal portions. One portion of the
sample was injected to LC-ESI MS to confirm whether the glycans
had been fully desialylated and the other two portions of the sample
was digested with 1–3,4 fucosidase (0.5 mU, 1 l) and 1–4 galac-
tosidase (0.3 mU, 1 l), respectively, at 37 °C for 1 h. After stopping
the reaction at 99 °C for 2 min, each digested sample was analyzed
by LC-EIS MS and compared with the original structures.
Analysis of Glycans on Glycoproteins Separated on SDS-PAGE—
Cell membranes from 4  107 cells were prepared as above and the
acetone-precipitated proteins were dissolved in water (13 l), 500 mM
dithiotreitol (2 l) and LDS buffer (5 l), heated at 70 °C for 10 min,
and 10 l was separated by SDS-PAGE. After the electrophoresis,
proteins were transferred to PVDF membrane under semiwet condi-
tions by means of a Novex Mini-Cell (Invitrogen) in transfer buffer
(0.1 M Glycine, 0.012 M Tris, and 20% (v/v) methanol). The PVDF
membrane was washed three times with water for 1 min each. The
proteins on PVDF membrane were stained with Direct Blue 71. After
destaining, the PVDF membrane was dried at room temperature for
4 h and the protein bands cut into pieces (0.5  0.5 cm), combined
together as five different molecular weight range fractions (35 kDa,
35–55 kDa, 55–85 kDa, 85–200 kDa, and200 kDa) in separate wells
of a 96-well microtiter plate, and the N-glycans released and analyzed
as above.
Measurement of ST6Gal Enzyme Activity with 2-Aminopyridine
(PA)-labeled N-glycan as Acceptor—The measurement of the activity
of ST6Gal was performed by an adaptation of the method of Dall’Olio
et al. (13). Their method is based on the enzyme-catalyzed transfer of
radioactive sialic acid from the donor substrate (CMP-[14C]NeuAc) to
an acceptor that is an asialo-glycan. In this study we used the fluo-
rescently PA-labeled biantennary asialo-N-glycan (Takara bio, Shiga,
Japan) as acceptor and unlabeled CMP-NeuAc (Calbiochem, La Jolla,
CA) as donor substrate. Cells (1  107) were homogenized by vigor-
ous pipeting up and down (50 times) in 40 l of ice-cold water. To the
homogenized solution, 4 l of 1 M sodium cacodylate (pH 6.5), 2.5 l
of 10% Triton X-100, 2 l of PA-labeled biantennary asialo-N-glycan
(20 pmol), and 1 l of CMP-NeuAc (1.5 nmol) were added and the
mixture was incubated at 37 °C overnight. Water (2 l) was added
instead of the acceptor as a control. After incubation, water (100.5 l)
was added to the reaction mixture, and the mixture was filtered
through a 10 kDa molecular weight cutoff membrane filter (Nanosep,
PALL life sciences, Port Washington, NY) using centrifugation
(12000 g, 10 min). The retentate on the membrane was washed with
50 l of water, and the washing combined to give a resulting total
volume of 200 l. A portion (10 l) of the solution was separated by
normal phase HPLC with a Shimadzu 10A HPLC system equipped
with a fluorescence detector (Shimadzu RF-10AXL). Separation was
carried out at a flow rate of 0.2 ml/min at 50 °C using a polymer-based
Asahi Shodex NH2P-50 2D column (Showa Denko, Tokyo, Japan; 2
150 mm) with a linear gradient formed by 2% acetic acid in acetoni-
trile (solvent A) and 5% acetic acid in water containing 3% triethyl-
amine (solvent B). The column was initially equilibrated and eluted
with 20% solvent B for 2 min, at which point the concentration of
solvent B was increased to 80% over 60 min. Next the column was
washed with 95% solvent B for 15 min and equilibrated with 20%
solvent B for 25 min. The PA-labeled acceptor (biantennary asialo-N-
glycan) and product (biantennary sialo-N-glycans), were measured by
fluorescence detection at ex  320 nm and em  400 nm.
LC-ESI MS of PA-labeled Glycans—PA-labeled N-glycans were
collected from the HPLC analysis and were analyzed by LC-ESI MS in
order to identify the linkage and the position of the sialic acid added
to the acceptor glycan. The analytical conditions were the same as
LC-ESI MS for analysis of N-glycan alditols with a different separation
gradient: a sequence of an isocratic and two segmented linear gra-
dients: 0–8 min, 10 mM NH4HCO3; 8–65 min, 2.25–22.5% CH3CN in
Alterations of Glycans in Drug Resistance
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10 mM NH4HCO3; 65–73 min, 22.5–45% CH3CN in 10 mM NH4HCO3;
and then stepping up to 81% CH3CN in 10 mM NH4HCO3 which was
kept for 6 min (to clean the column) and back to 10 mM NH4HCO3 for
4 min (to re-equilibrate) was used.
Cell Staining with Fluorescently Labeled Lectins—Cultured cells
(2  106) were washed twice with 1 ml of cold PBS using centrifuga-
tion (370  g, 7 min, 4 °C). The cell pellet was mixed with biotin
conjugated Sambucus sieboldiana (SSA) lectin (1 g in 50 l of PBS,
J-OIL MILLS, INC., Tokyo, Japan) or biotin conjugated Maackia amu-
rensis (MAM) lectin (1 g in 50 l of PBS, J-OIL MILLS, INC., Tokyo,
Japan), and kept on ice for 30 min. After washing with cold PBS using
centrifugation (370  g, 7 min, 4 °C), the cell pellet was mixed with
streptavidin conjugated R-phycoerythrin-cyanine dye (PE-Cy7) (0.5
g in 50 l of PBS, BD Biosciences) and kept on ice for 30 min. After
washing with cold PBS using centrifugation (370  g, 7 min, 4 °C)
three times, the cell pellet was suspended by vigorous pipeting up
and down (35 times) in 20 l of cold PBS. All samples were observed
using a Nikon Eclipse E600 fluorescence microscope (Tokyo, Japan).
Quantitative Real Time RT-PCR of ST6GAL-I—Cells were har-
vested during their mid-log cellular growth phase of 5  105-1  106
cells/ml and cell pellets were frozen and stored at 80 °C until re-
quired for RNA isolation. RNA isolation was performed using the
RNAeasy Plus Mini Kit (Qiagen) according to manufacturer’s instruc-
tions. RNA concentration was determined using the NanoDrop® ND-
1000 spectrophotometer. Two hundred nanogram of RNA was re-
verse transcribed in a total volume of 10 l. Quantitative Real Time
RT-PCR (qRT-PCR) was performed to determine the relative gene
expression of ST6GAL-I in the CEM and CEM/dEpoB300 cells. PCR
reactions were carried out using 1 l of cDNA, 2  TaqMan Gene
Expression Master mix, 20  ST6GAL-I TaqMan Gene Expression
(Applied Biosystems, assay ID Hs00949382), and two independent
housekeeping genes, human Cyclophilin A (PPIA) and human large
ribosomal protein (RPLPO) (Applied Biosystems) were used as control
genes. Conditions for the qRT-PCR on the ABI Prism 7900 HT (Ap-
plied Biosystems) were 2 min at 50 °C, followed by 40 cycles of
denaturation for 10 min at 95 °C, annealing and extension for 1min at
60 °C. Data analysis was performed using the SDS 2.3 Software
(Applied Biosystems) and the relative gene expression of ST6GAL-I
was calculated using the CT method, formula  (2CT), CT 
CT (CEM/dEpoB300) – CT (CEM) where CT  average CT value
of the gene of interest (ST6GAL-I) – average CT value of the control
gene (PPIA/RPLPO). Data represent three individual experiments per-
formed in triplicate.
RESULTS
Characterization of Glycan Structures on Membrane Pro-
teins of CEM and CEM/dEpoB Resistant Leukemia Cells—N-
Glycans were released from cell membrane glycoproteins by
PNGase F and were analyzed by LC-ESI MS and MS/MS as
N-glycan alditols. The base peak chromatograms (BPC) of the
separated N-glycans (Fig. 1A–1C) showed that the global
profile of the glycan structures on the cell membrane glyco-
proteins of CEM cells were different from that of CEM cells
selected for resistance to 30 nM dEpo30 (CEM/dEpoB30) and
300 nM dEpoB (CEM/dEpoB300). The numbers attached to
each peak in Fig. 1 correspond to the identification of 20
glycan masses comprising 47 different N-glycan structures as
summarized in Fig. 2. These structures included high man-
nose type N-glycans (structures #1–5), asialo-N-glycans
(structures #6–10), monosialo-N-glycans (structures #11, 12,
15, 16), disialo-N-glycans (structures # 13, 14, 17), trisialo-N-
glycans (structures # 18, 19), and a tetrasialo-N-glycan (struc-
ture # 20) with and without fucosylation and with different
sialylation linkages and positions. The relative abundances
(%) of each glycan structure on the cell membrane glycopro-
teins of the three cell lines are shown in Fig. 2. This was
calculated by setting the total peak area of glycans in each
BPC as 100%, and the relative abundance (%) was calculated
using the area under the EIC peak for each glycan structure.
High mannose type N-glycans, (structures # 1  23  45)
in CEM cell, CEM/dEpoB30, and CEM/dEpoB300, were ob-
served in large amounts in all three cell lines and comprised
34.3%, 40.7%, and 36.6% of the total glycan structures on
the cell membrane glycoproteins respectively.
Fucosylated monosialo-N-glycans (structure # 12, 1038.9
m/z [M-2H]2) were observed as the major complex type
N-glycans on all cells with a different distribution of isomers.
This N-glycan composition (structure # 12) presents as four
structural isomers with different retention times; #12a (42
min), #12b (44 min), #12c (54 min), and #12d (55 min) in the
BPC in Fig. 1A-C. Fucosylated disialo-N-glycans (structure #
14, 1184.4m/z [M-2H]2) were observed as the second major
complex type N-glycans with a similar different distribution of
isomers between the cell types. This N-glycan mass (structure
#14) has three structural isomers; #14a (49 min), #14b (58
min), and #14c (60 min) that were separated by graphitized
carbon column chromatography (Fig. 1A–1C).
To determine the exact structural differences between
these isomers, specific sialidases were used to characterize
the linkage of NeuAc to galactose (Gal). The total released
N-glycans from the CEM cell glycoproteins (Fig. 3A) were
treated with 2-3 sialidase (Fig. 3B), 2–3,6 sialidase (Fig. 3C),
and 2–3,6,8,9 sialidase (Fig. 3D), respectively. The EICs at
1184.4 m/z [(fucosylated disialo-biantennary N-glycan (struc-
ture #14)], 1038.9 m/z [fucosylated monosialo-biantennary
N-glycan (structure #12)] and the fully desialylated bianten-
nary product mass at 893.3 m/z [fucosylated asialo-bianten-
nary N-glycan (structure #7)] were chosen to monitor the
effect of the sialidase digestions of these mono-sialylated and
di-sialylated N-glycans. The structures #14b and #14c disap-
peared and the structures #12b and #7 increased after 2-3
sialidase (Fig. 3B), indicating that the isomers consist of bi-
antennary structures with one 2-3 NeuAc and two 2-3
NeuAc on the termini, whereas #12a, #12b, and #14a did not
disappear, indicating that their structures do not contain ter-
minal 2-3 NeuAc. Structures #12c and #12d both moved to
the retention time of structure #7 after 2-3 sialidase diges-
tion, indicating that these mono-sialylated structures are
linked to 2-3 NeuAc. After digestion with 2–3,6 sialidase
and 2–3,6,8,9 (Fig. 3C and 3D), all structures were fully
de-silaylated (to structure #7). In summary, N-glycan struc-
tures #12a, #12b, and #14a consist of NeuAc linked only as
2–6, and #12c, 12d, and 14c consist of NeuAc linked only as
2–3, and #14b consists of both 2-3 NeuAc and 2–6
NeuAc linkages.
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The linkage position of NeuAc on the mono-sialylated bi-
antennary N-glycan structures #12a-d was also determined
from their MS/MS spectra. For this determination, N-glycans
of bovine fetuin, whose structures were already identified in
detailed by Townsend et al. (14) and Green et al. (15), were
analyzed by LC-ESI MS and MS/MS (supplemental Fig. S1)
and used as standard structures for comparison. The fetuin
bi-antennary and tri-antennary N-glycan isomers, which in-
clude sialic acids (NeuAc) attached with different linkages and
positions were observed in the BPC (supplemental Fig. S1A).
The EIC of the monosialo-bi-antennary N-glycans (structure #
11, 965.8 m/z [M-2H]2) (16) showed the presence of 4 iso-
mers (supplemental Fig. S1B), and each isomeric ion was
subjected to MS/MS analysis. We found a diagnostic ion in
the MS/MS spectra which was able to distinguish the sialy-
lated mannose branch of the monosialo-bi-antennary N-gly-
cans. If NeuAc is located on the 1–6 Man branch of this
structure, a fragment ion at 979.3 m/z, which corresponds to
the mass of [NeuAc-Gal-GlcNAc-Man-1–6 Man], was ob-
served (supplemental Fig. 2A and 2C), whereas this fragment
is not seen in the MS/MS spectrum if NeuAc is located on the
1–3 Man branch (supplemental Fig. 2B and 2D).
N-glycan structural isomers #12a-d released from the CEM
cell glycoproteins (as shown in Fig. 3A) were subjected to
MS/MS analysis, and this diagnostic ion fragment ion of 979.3
m/z was not observed in the MS/MS spectra of N-glycan
structures #12b and 12d (Figs. 3E and 3F) but was observed
in MS/MS fragmentation spectra of N-glycan structures #12a
and 12c (data not shown). Thus it can be deduced that the
mono-sialylated bi-antennary N-glycan structures #12a and
#12c are sialylated on the 1–6 Man branch whereas struc-
tures #12b and #12d have NeuAc on the 1–3 Man branch.
The linkage of fucose (Fuc) on the N-glycans was charac-
terized using specific fucosidase and galactosidase diges-
FIG. 1. LC-ESI MS analysis of N-glycans and O-glycans released from cell membrane glycoproteins. A–C; BPC for N-glycans from
CEM cell (A), CEM/dEpoB30 cell (B) and CEM/dEpoB300 cell (C). D–E; BPC for O-glycans from CEM (D), CEM/dEpoB30 cell (E) and
CEM/dEpoB300 cell (F). G–I: EIC at 1038.9 m/z for fucosylated monosialo-bi-antennary N-glycan (structure # 12), J–L: EIC at 1184.4 m/z for
fucosylated disialo-bi-antennary N-glycan (structure # 14). The structures of N-glycans and O-glycans are shown in Fig. 2.
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tions. The results of digestions of the disialo-bi-antennary
N-glycan with one Fuc (structure #14) and trisialo-tri-anten-
nary N-glycan with one Fuc (structure #19) are shown in
supplemental Fig. S3 and supplemental Fig. S4, respectively.
Using 1–3,4 fucosidase after desialylation with mild acid did
not result in a change in retention or mass of the desialylated
structures. In addition, beta1–4 galactosidase resulted in re-
moval of the mass of galactose; because this enzyme can
only remove terminal galactose if it is not fucosylated, it was
deduced that the Fuc on the biantennary and triantennary
N-glycans is 1–6 linked core fucose. Bi-antennary N-glycans
with two Fuc (structure #8 and #15) were also observed in this
study. After digestion with 1–3,4 fucosidase, the bi-anten-
nary N-glycan with two Fuc (structure #8) was no longer
observed. After further digestion with 1–4 galactosidase,
the bi-antennary N-glycan lost one Gal (structure #33 in
supplemental Fig. S3D). These results showed the linkages
of Fuc on the biantennary N-glycans (structure #8 and #15)
were 1–6 (core Fuc) and 1–3,4 (Lewisx/a Fuc). Sialylated
fucosylated tetra-antennary N-glycans (structure #20) were
also observed, but the linkage of Fuc could not be identified
as they were in low abundance (CEM; 0.09%, CEM/
dEpoB30; 0.04%, CEM/dEpoB300; 0.14%). The detailed
N-glycan structures found in CEM cell, CEM/dEpoB30 cell,
and CEM/dEpoB300 cell were characterized in this way and
are shown in Fig. 2.
Thus we show that high mannose N-glycans comprise the
major structures in all the cell lines, but that the major com-
plex type core fucosylated monosialo-biantennary N-glycans
in CEM and CEM/dEpoB30 cells are 2–6 NeuAc sialylated
(structure #12b, 10.3%, and 7.0%, respectively), whereas the
N-glycans of the drug resistant CEM/dEpoB300 cells are sia-
lylated with 2-3 NeuAc linkage (structure #12d, 7.2%). In
addition, the 2-3 NeuAc sialylation of the core fucosylated
disialo-biantennary N-glycans increases markedly in the
drug resistant CEM/dEpoB300 cells (structure #14c, 6.0%)
relative to the control CEM cells. It is clear from this analysis
that the N-glycans on the membrane glycoproteins of leu-
kemia cells change with acquired resistance to dEpoB and
that this change is related to different sialylation of the
N-glycans.
O-Glycans were released by chemical -elimination from
the same cell membrane glycoproteins after the enzymatic
release of N-glycans and were also analyzed by LC-ESI MS
and MS/MS as O-glycan alditols. The BPC in Figs. 1D–1F
showed that the chromatographic profile of O-glycan struc-
tures on the cell membrane glycoproteins of CEM, CEM/
dEpo30, and CEM/dEpoB300 cells were similar. For identifi-
cation of O-glycan structures, O-glycans of bovine fetuin,
whose structures have already been identified in detail by
Karlsson et al. (17) and Royle et al. (18), were analyzed by
LC-ESI MS and used as standard structures for comparison
of retention time and fragmentation spectra. Specific siali-
dases were also used to characterize the linkage of NeuAc to
Gal on the O-glycans of the CEM, CEM/dEpo30, and CEM/
dEpoB300 cell membrane glycoproteins (data not shown).
The ten O-linked structures identified are shown in Fig. 2,
including a low abundance sulfated O-glycan (structure #26).
Sialylation linked to Gal residue appears to be all 2-3 NeuAc
with some increased desialylation present in the dEpoB30
mildly resistant cells (structure #21 and #25, CEM/dEpo30)
(Fig. 2).
Relative Quantification of Sialylated Glycan Isomers on
Membrane Glycoproteins of CEM and dEpoB Resistant Leu-
kemia Cells—EIC areas were used for comparison of the
relative amount of the different sialoforms of bi-antennary
N-glycan, tri-antennary N-glycan, and tetra-antennary N-gly-
can structures with and without fucose in CEM, CEM/
dEpoB30, and CEM/dEpoB300 cells. The EIC of 1038.9 m/z
[core fucosylated monosialo-bi-antennary N-glycan (structure
#12)] in Fig. 1G–1I shows that an isomer with a NeuAc in 2-3
linkage (structure #12d) is most abundant in CEM/dEpoB300
compared with both CEM and CEM/dEpoB30 cells. Also the
EIC of 1184.4 m/z [core fucosylated disialo-bi-antennary N-
glycan (structure #14)] in Fig. 1J–1L shows that an isomer with
both NeuAc additions in an 2-3 linkage (structure #14c) is
most abundant in CEM/dEpoB300 cells. Other sialylated iso-
mers are also seen to change in dEpoB300 cells; EIC of
1111.4 m/z [disialo-bi-antennary N-glycan (structure #13);
supplemental Fig 5A–C] shows an increased isomer where
both NeuAc are 2-3 linked (structure #13c) and, although the
exact linkage and the position of NeuAc on the fucosylated
disialo-tri-antennary N-glycan (EIC of 1367.0 m/z) could not
be characterized, the typically later elution position of 2-3
NeuAc linked isomers off the carbon column indicates that the
more abundant structure #17c (supplemental Fig. 5D–F) has
two 2-3 NeuAc. This difference in sialylation was not appar-
ent in the less resistant dEpoB30 cells. Cells selected for
resistance to 60 nM dEpoB (CEM/dEpoB60) or 140 nM dEpoB
(CEM/dEpoB140) also did not show a significant change in
NeuAc linkage [(structure #14) in supplemental Fig. 6]. These
results demonstrate clearly that 2-3 linked NeuAc is the
dominant linkage on all N-glycans in the highest resistant
cells, CEM/dEpoB300, compared with the CEM cells from
FIG. 2. Bar graph of relative quantification of N-glycans and O-glycans observed in this study. Symbols of monosaccharides and sulfonic
residue (HSO3) are shown in the panel at the lower right hand side. The number in parenthesis is mass numbers represented as [M-2H]
2 of
alditol N-glycans and [M-H] of alditol O-glycans. The relative abundance (%) was calculated based on the peak area of EIC corresponding
to glycans obtained from the results presented in Fig. 1. The error bar represents the standard deviation (S.D.) calculated from each type of
cell (n  3). To compare three groups [CEM, CEM/dEpoB30 and CEM/dEpoB300] repeated measures ANOVA (two-tail) was used, and then
each groups of two was compared by Bonferroni correction (two-tail). The annotations in this figure indicate p  0.01.
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which they are derived, and that the 2–6 NeuAc linkage has
been globally reduced on all N- glycan structures on the cell
membrane proteins.
We also analyzed the O-glycans on the membrane glyco-
proteins of CEM, CEM/dEpoB30 and CEM/dEpoB300 cells.
The EIC of the major sialylated O-glycan isomers of 675.2m/z
(supplemental Fig. 5G–I) showed no difference in these cells
and there was also no alteration of the sialylation of the
O-glycans in CEM/dEpoB60 and dEpoB140 resistant cells
(data not shown). However, we did find an O-glycan structure
that was not present only in the CEM/dEpoB 300 cells, which
was identified as having the composition of a sulfated
(HexNAc)2(Hex)2 (structure #26, supplemental Fig. 5J–L).
There are three possible structures for this sulfated O-tetrasa-
ccharide [(i)–(iii), supplemental Fig. 5M). The possible struc-
tures with sulfate attached to Gal in a linear structure (i) (19),
or attached to Gal (ii) (20), or attached to GlcNAc (iii) (21) in a
branched structure, have been found in mucus glycoproteins
in human respiratory systems. The sulfated O-glycan struc-
ture was characterized using MS/MS (supplemental Fig. 5N)
and the diagnostic fragment ion at 505.1 m/z represented a
sulfated HexNAc-HexNAc-OH which identified that the par-
ticular sulfated structure lost from the glycoproteins of
dEpoB300 cells was Gal (1–4) [HSO3(-6)]GlcNAc (1–6)
[Gal(1–3)]GalNAc (iii).
Sialylation Changes on Cell Membrane Glycoproteins—To
determine whether the alteration in sialylation associated with
acquired resistance to the dEpoB drug occurred to N-glycans
on a particular cell membrane glycoprotein, we analyzed the
N-glycan structures on cell membrane glycoproteins sepa-
rated based on molecular weight. Enriched cell membrane
proteins purified by detergent phase partitioning were sepa-
rated by SDS-PAGE (Fig. 4A), and electroblotted to PVDF
membrane. After staining proteins with Direct blue 71, the
protein bands were cut out at five molecular weight ranges,
approximately 35 kDa, 35–55 kDa, 55–85 kDa, 85–200 kDa,
and 200 kDa. N-Glycans from the five molecular weight
bands were released and analyzed by LC-ESI MS and MS/
MS. The EIC of 1184.4 m/z [core fucosylated disialo-bianten-
nary N-glycan (structure #14)] showed that the major isomer
of this N-glycan in CEM cells was structure #14b (terminated
with one 2–6 NeuAc and one 2-3 NeuAc, Fig. 4B) in all five
molecular weight bands whereas the major isomeric change
to structure #14c (both branches terminated by 2-3 NeuAc,
Fig. 4C) occurred in all molecular weight bands of membrane
proteins extracted from CEM/dEpoB300 cells. That is, it is
clear that the reduction in 2–6 NeuAc sialylation has oc-
curred on the N-glycans of all, or at least most, of the cell
membrane glycoproteins.
Cell Staining with Fluorescently Labeled Lectins—Cell
staining with fluorescently labeled lectins was carried out in
order to confirm that the decrease of 2–6 sialylated N-
glycans in CEM/dEpoB300 cells was not caused by an in-
crease of 2-3 sialylated N-glycans. CEM and CEM/
dEpoB300 cells were reacted with biotin conjugated Sam-
bucus sieboldiana (SSA) lectin (recognizes 2–6 sialylated
glycans) or biotin conjugatedMaackia amurensis (MAM) lectin
FIG. 3. Characterization of the linkage and position of sialic
acids on fucosylated monosialo-bi-antennary N-glycans (struc-
ture # 12) and fucosylated disialo-bi-antennary N-glycans
(structure # 14) on membrane glycoproteins of CEM cells using
3 kinds of specific sialidase and MS/MS. A–D: EIC at 1184.4 m/z
for fucosylated disialo-biantennary N-glycan (structure # 14), EIC at
1038.9 m/z for fucosylated monosialo-biantennary N-glycan (struc-
ture # 12), EIC at 893.3 m/z for fucosylated asialo-biantennary
N-glycan (structure # 7) before sialidase (A), after 2-3 sialidase (B),
after 2–3,6 sialidase (C), and after 2–3,6,8,9,sialidase (D). E and
F: MS/MS analysis of two isomers of fucosylated monosialo-bi-
antennary N-glycans (structures # 12b and 12d) observed in Fig.
3A, respectively.
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(recognize 2-3 sialylated glycans). The reacted cells were
mixed with streptavidin conjugated R-phycoerythrin-cyanine
dye (PE-Cy7), and were observed using fluorescence micros-
copy (Fig. 5). In CEM/dEpoB300 cells, the number of cells
recognized with SSA lectin was seen to decrease, but number
of cells recognized with MAM lectin did not change when
compared with lectin labeled CEM cells. This result showed
2–6 sialylated N-glycans decreased without an apparent
increase of 2-3 sialylated N-glycans in the drug resistant
CEM/dEpoB300 cells and corroborates the glycan analysis
data. This decrease of 2–6 sialylation on the N-glycans of all,
or at least most, of the cell membrane glycoproteins may
presumably be caused by a decrease of expression and/or
activity of the 2–6 sialyltransferase (ST6Gal), which cata-
lyzes the addition of sialic acids, via a NeuAc 2–6-Gal link-
age, to the terminal Gal of glycoconjugates.
Quantitative Real Time RT-PCR of ST6GAL-I—To test
whether there is a decrease in the expression of ST6Gal in the
drug resistant CEM/dEpoB300 cells, we determined the rela-
tive gene expression of ST6GAL-I in CEM and CEM/
dEpoB300 cells by quantitative Real Time RT-PCR (qRT-PCR)
using two independent reference housekeeping genes, hu-
man Cyclophilin A (PPIA) and human large ribosomal protein
(RPLPO). The relative gene expression of ST6GAL-I was cal-
culated using the CT method. The data representsthree
individual experiments performed in triplicate (Fig. 6). Consis-
tent with the decrease in 2–6 sialic acid on the N-glycans,
there was a measured decrease in expression of ST6GAL-I in
FIG. 4. N-glycan structures on fractions of cell membrane pro-
teins separated by SDS-PAGE. A, SDS-PAGE of the total cell mem-
brane proteins from CEM cell and CEM/dEpoB300 cells. EIC of
1184.4 m/z corresponding to fucosylated disialo-bi-antennary N-gly-
can (structure #14) on cell membrane proteins separated into five
different molecular weight ranges (35 kDa, 35–55 kDa, 55–85 kDa,
85–200 kDa and 200 kDa) derived from CEM cell (B) and CEM/
dEpoB300 cell (C).
FIG. 5. Cell staining with fluorescently labeled lectins. CEM cells
and CEM/dEpoB300 cells were stained with PE Cy7-labeled SSA
lectin and MAM lectin via biotin-streptavidin binding. SSA lectin and
MAM lectin recognize 2–6 sialic acids and 2-3 sialic acids,
respectively.
FIG. 6. Quantitative Real Time RT-PCR of ST6GAL-I. The relative
gene expression of ST6GAL-I in CEM and CEM/dEpoB300 cells were
determined using two independent housekeeping genes, human Cy-
clophilin A (PPIA) and human large ribosomal protein (RPLPO). Three
individual experiments were performed in triplicate.
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CEM/dEpoB300 cells (43% relative to ST6GAL-I in CEM cells
(when used PPIA as control gene), and 37% relative to
ST6GAL-I in CEM cells (when used RPLPO as control gene)),
however this did not achieve statistical significance using the
unpaired, two tailed t test with 95% confidence interval for the
nine runs.
Activity of ST6Gal in CEM and CEM/dEpoB Cells—The
activity of ST6Gal expressed in CEM cell and CEM/dEpoB
cells was tested by HPLC analysis of the conversion of a
fluorescently labeled substrate to its 2–6 sialylated product
(Fig. 7A–7C). PA-labeled bi-antennary asialo-N-glycan as ac-
ceptor, and CMP-NeuAc as donor substrate, were mixed with
a cell lysate of CEM (107 cells) and CEM/dEpoB300 (107 cells).
After overnight incubation, the PA-labeled bi-antennary sialo-
N-glycan product was measured by HPLC with fluorescence
detection. In Fig. 7B–7C, the fluorescence peak at retention
time 28.0 min is the nonreacted excess acceptor glycan, and
the peak at 36.0 min is the product glycan. The peaks marked
with an asterisk are derived from the cell lysate and are
unrelated to the reaction (see blank sample analysis in
supplemental Fig. 7B–C). The results of this assay with cells
selected at lower levels of drug resistanceCEM/dEpoB60,
CEM/dEpoB140 and CEM/dEpoB300 are shown in
supplemental Fig. 7D–H. We found the 2–6 sialylated prod-
uct glycan to be synthesized by all cells except the CEM/
dEpoB300 cells.
As there is no commercially available PA-labeled mono-
sialo-bi-antennary N-glycan standard, with a 2-3 NeuAc link-
age, with which to compare the retention time, the bi-anten-
nary sialo-N-glycan product was collected from the HPLC
column (Fig. 7B) and was analyzed by LC-ESI MS and MS/MS
to determine the linkage of the NeuAc. The mass of the
product glycan at 36.5 min was 1003.9 m/z (Fig. 7D), corre-
sponding to the mass of a PA-labeled monosialo-biantennary
N-glycan. Digestion with 2-3 sialidase did not change either
the retention time or the mass of the product peak (Fig. 7E)
whereas digestion with 2–3,6 sialidase changed the reten-
tion and mass of the product peak to that of a PA-labeled
asialo-biantennary N-glycan (33.5 min, 858.3 m/z; Fig. 7F).
Thus the product glycan from the assay of ST6Gal-I in Fig.
7B–7C was confirmed to be a PA-labeled 2–6 NeuAc mono-
sialo-bi-antennary N-glycan. Further structural analysis by
MS/MS of this product glycan showed that the diagnostic
fragment ion of 979.3 m/z (diagnostic of the sialylation of the
FIG. 7. Determination of the activity of ST6Gal-I enzyme in CEM and CEM/dEpoB300 cells. A–C: HPLC analysis using PA-labeling
biantennay glycan as acceptor and CMP-NeuAc as donor substrate. A, Principle of this determination. B and C, HPLC of cell lysate of CEM
cells (B) and CEM/dEpoB300 cells (C). Peak at 36.0 min in chromatogram (B) and (C) is the product glycan, and asterisked peaks are derived
from cell lysate and are not related to glycans (see supplemental Fig. 7B and C). D–G: MS and MS/MS analysis of the product glycan collected
from HPLC separation shown in (B). BPC and mass of the product glycan (D) after treatment with 2-3 sialidase (E) and 2–3,6 sialidase (F).
G, MSMS analysis of the peak observed at 36.5 min in (D).
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1–6 Man branch of both a reduced or PA-derivatized bian-
tennary N-glycan; supplemental Fig. 2) was not observed (Fig.
7G), thus locating the 2–6 NeuAc on the 1–3 Man branch of
the bi-antennary N-glycan. The product glycan in Fig. 7B–7C
were thus confirmed to be an 2–6 sialylated N-glycan, which
would be produced by ST6Gal-I, and not by -galactoside
2–3- sialyltransferase (ST3Gal).
Based on peak area of 1 pmole standard PA-labeled bi-
antennary asialo-N-glycan acceptor (supplemental Fig. 7A)
the amount of product formed was calculated from the area of
the peaks. Using a lysate from the same cell number (107
cells), the CEM cell activity resulted in 608 fmol acceptor
glycan remaining and 57.6 fmol of mono-sialylated product
glycan formed i.e. 8.65% yield (Fig. 7B). This compared with
the activity of the dEpoB300 cell lysate of 481 fmol remaining
substrate and 6.74 fmol product i.e. 1.38%, yield (Fig. 7C).
Therefore, the ST6Gal-I activity in the dEpoB300 resistant
cells was 	6 times less than that in the CEM cells.
DISCUSSION
Detailed analysis of the N-glycan and O-glycan structures
on leukemia cell membrane proteins that have acquired re-
sistance to the tubulin-binding antitumor drug dEpoB showed
changes to the membrane glycosylation of the cells. Specifi-
cally there was a significant decrease of 2–6 sialylation of
the N-glycans on all, or at least most, of the cell membrane
glycoproteins. We have determined that this change was
caused by a decrease in enzyme activity of ST6Gal and was
potentially associated with a decrease in expression of
ST6GAL-I gene. This decrease of 2–6 sialylation was not
observed on the O-glycans because these structures do not
contain the ST6Gal-I substrate structure of Gal1–4GlcNAc
(23). Two homologs of human ST6Gal have been reported,
designated ST6Gal-I and ST6Gal-II. ST6Gal-I has been found
in Golgi apparatus as a single-pass type II membrane protein
and in the body fluid as a secreted protein (24–26). This gene
is ubiquitously expressed, as an enzyme composed of 406
amino acids (mass: 46605 Da) with two potential N-glycan
binding sites (27). Interestingly, this enzyme preferentially
adds 2–6 NeuAc to Gal1–4GlcNAc residues on the
Man1–3Man branch rather than the Man1–6Man branch of
bi- and tri-antennary N-glycans (28, 29), which agrees with the
branch position of the 2–6 NeuAc structures found to be
missing in the CEM/dEpoB drug resistant cells in this study.
ST6Gal-II is also found in Golgi apparatus as a single-pass
type II membrane protein. The sequence encodes a protein of
529 amino acids (mass: 60158 Da) with 48.9% amino acid
sequence identity to ST6Gal-I (22). This enzyme is weakly
expressed in some tissues, such as small intestine, colon and
fetal brain, and has one potential N-glycan binding site.
In our previous study that described the development and
characterization of the CEM/dEpoB resistant cells (30), we
identified two I-tubulin mutations which are involved in drug
binding and microtubule stability. The CEM/dEpoB resistant
sublines did not display increased expression of the multidrug
transporters MDR1 or MRP1, nor did they exhibit reduced
paclitaxel accumulation (6). Paclitaxel is a hydrophobic agent,
whereas dEpoB is hydrophilic and enters cells via a distinct,
yet undetermined cell transport mechanism. In this study, we
used a detailed analysis of the products of the cellular glyco-
sylation synthesis pathways to find that the resistance to
these drugs also results in a decrease in activity of ST6Gal-I.
ST6Gal-I is an enzyme that adds a charged sialic acid mon-
osaccharide, in a highly specific 2–6 linkage, to the terminus
of all N-glycans, seemingly on all membrane proteins of the
cells. We could speculate that the resultant change in overall
membrane charge may allow dEpoB300 resistant cells to
change the transport of the drug into the cell and escape
apoptosis.
We also analyzed the N-glycans on the cell membrane
proteins of CEM cells resistant to vincristine (3 nM), another
tubulin-binding antitumor drug that inhibits assembly of mi-
crotubule structures. The vincristine-resistant cells lost almost
all sialylation of their N-glycans (both 2–6 NeuAc and 2-3
NeuAc) (supplemental Fig. 8A–E). As in the case of epothilone
B resistance, this decrease of sialylation was observed on all
cell membrane glycoproteins (supplemental Fig. 8F–K). This
suggests that loss of sialylation on the N-glycans of mem-
brane proteins may be a general mechanism of acquiring
resistance to tubulin-binding antitumor drugs. The role of
sialylation in the acquisition of resistance to these drugs is
unknown at this stage and will be the subject of further
investigation. In therapeutic terms, the connection between a
change to such a specific modification on the surface of the
cells and the mechanism of this downstream effect of micro-
tubule targeting drugs may offer a route to new interventions
to overcome drug resistance.
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